Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)

Stefanie A. Boer; Melanie Reijrink; Wayel H. Abdulahad; Elisa S. Hoekstra; Riemer H. J. A. Slart; Hiddo J. L. Heerspink; Johanna Westra; Douwe J. Mulder

doi:10.1111/dom.14024

Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)

Diabetes Obesity and Metabolism ◽

10.1111/dom.14024 ◽

2020 ◽

Vol 22 (7) ◽

pp. 1220-1225

Author(s):

Stefanie A. Boer ◽

Melanie Reijrink ◽

Wayel H. Abdulahad ◽

Elisa S. Hoekstra ◽

Riemer H. J. A. Slart ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

T Cells ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Release Study ◽

Angiogenic T Cells

Download Full-text

Decision letter for "Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study)"

10.1111/dom.14024/v1/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

T Cells ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Release Study ◽

Angiogenic T Cells

Download Full-text

Decision letter for "Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study)"

10.1111/dom.14024/v2/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

T Cells ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Release Study ◽

Angiogenic T Cells

Download Full-text

Review for "Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study)"

10.1111/dom.14024/v1/review3 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

T Cells ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Release Study ◽

Angiogenic T Cells

Download Full-text

Review for "Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study)"

10.1111/dom.14024/v1/review1 ◽

2020 ◽

Author(s):

Adriana Georgescu

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

T Cells ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Release Study ◽

Angiogenic T Cells

Download Full-text

Author response for "Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study)"

10.1111/dom.14024/v2/response1 ◽

2020 ◽

Author(s):

Stefanie A. Boer ◽

Melanie Reijrink ◽

Wayel H. Abdulahad ◽

Elisa S. Hoekstra ◽

Riemer H.J.A. Slart ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

T Cells ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Release Study ◽

Angiogenic T Cells

Download Full-text

Review for "Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study)"

10.1111/dom.14024/v1/review2 ◽

2020 ◽

Author(s):

Winfried Graninger

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

T Cells ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Release Study ◽

Angiogenic T Cells

Download Full-text

The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2013.12.039 ◽

2014 ◽

Vol 103 (3) ◽

pp. 395-401 ◽

Cited By ~ 12

Author(s):

P.C.M. van Poppel ◽

M.S. Gresnigt ◽

P. Smits ◽

M.G. Netea ◽

C.J. Tack

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Ex Vivo ◽

Dipeptidyl Peptidase ◽

Cytokine Response ◽

Lymphocyte Function ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Clinical Drug Investigation ◽

10.1007/s40261-021-01088-5 ◽

2021 ◽

Author(s):

Lu Wang ◽

Jinmiao Lu ◽

Sufeng Zhou ◽

Yuqing Zhao ◽

Lijun Xie ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Food Effect ◽

Dipeptidyl Peptidase ◽

Pharmacokinetics And Pharmacodynamics ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2014.939070 ◽

2014 ◽

Vol 15 (13) ◽

pp. 1785-1795 ◽

Cited By ~ 2

Author(s):

Yuri Ono ◽

Hikaru Kamoshima ◽

Akinobu Nakamura ◽

Hiroshi Nomoto

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Japanese Patients ◽

Metabolic Responses ◽

Fixed Dose ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Dose Combination

Download Full-text

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin

Hypertension ◽

10.1161/hypertensionaha.116.07797 ◽

2016 ◽

Vol 68 (3) ◽

pp. 606-613 ◽

Cited By ~ 17

Author(s):

William B. White ◽

Craig A. Wilson ◽

George L. Bakris ◽

Richard M. Bergenstal ◽

Christopher P. Cannon ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Angiotensin Converting Enzyme ◽

Angiotensin Converting Enzyme Inhibitor ◽

Enzyme Inhibitor ◽

Converting Enzyme ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text